California bill to turn lost Pacific Palisades homes into affordable housing paused after locals call it ‘a land grab'
Now, the rebuilding process is leading to some conflict. Specifically, many residents of Pacific Palisades have recently expressed serious concerns about Senate Bill 549, which would create 'Resilient Rebuilding Authorities" funded by the government through property tax collection. These concerns were recently raised in a Fox 11 LA news report.
These authorities would be given the power to purchase lots where homes had been destroyed by fire, and to build low-income housing on a significant percentage of those lots.
However, residents of Pacific Palisades, where Realtor.com reports the median home listing price is $4.9 million, are not happy with what they see as a "land grab." Many have voiced opposition, and, in response, Senate Bill 549 has been put on hold until at least 2026.
Don't miss
Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how
I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 6 of the easiest ways you can catch up (and fast)
You don't have to be a millionaire to gain access to this $1B private real estate fund. In fact, you can get started with as little as $10 — here's how
What would the California affordable housing bill do?
Senate Bill 549 explains that existing law gives the government the authority to establish an "infrastructure financing district to finance public capital facilities or other specified projects of communitywide significance" and to "allocate tax revenues… to the district, including revenues derived from local sales and use taxes."
Lawmakers now want to use this power to create Resilient Rebuilding Authorities, which would use some of the money to buy lots in Pacific Palisades and build homes for people with incomes between 60% and 30% of the median income, as well as homes that would be occupied by people with incomes below 30% of the area median and permanent supportive housing aimed at finding homes for the homeless.
Governor Gavin Newsom also separately allocated $101 million in taxpayer money for the construction of more low-income housing to "accelerate the development of affordable multifamily rental housing so that those rebuilding their lives after this tragedy have access to a safe, affordable place to come home to."
Read more: Want an extra $1,300,000 when you retire? Dave Ramsey says — and that 'anyone' can do it
Why is the California housing bill causing so much controversy?
While lawmakers may want to build affordable housing in Pacific Palisades, residents are not so sure they want this to happen.
Jessica Rogers, Pacific Palisades Residents' Association president, wrote a letter expressing her objections to lawmakers, which over 2,300 other local residents signed onto.
"[Lawmakers are] asking for a land grab," Rogers said. "This is a rebuild, this is not a politicians get to decide a pet project on what they're going to decide in the Palisades. This is residents of this community get to decide what happens in our rebuild phase, period."
Rogers also stated that while there was some affordable housing in the area in the past, residents don't want more of this housing built because they don't want things to change — they want their neighborhood back the way it was.
"We had some low-income housing, and we had affordable housing," Rogers explained. "We want what we had on January 7 [the day of the Palisades Fire]. Nothing more, nothing less."
Another resident was also upset about the idea of the government coming in and making sweeping changes without the consent of those who already lived there. "It does sound quite a bit like Big Brother deciding what's good for all of us," commented Aileen Haugh, another local resident. "It's irritating to think that other people [not local residents] are going to make decisions of what gets built and how it gets built."
Misinformation may have also played a role in stoking opposition, as the LA Times reported that Spencer Pratt, a reality TV star, had shared information on social media about his opposition to the bill, who claimed that the government was focused on dense reconstruction and wouldn't be abiding by local zoning rules.
The LA Times has also said that some of the other posts opposing the legislation were based on prejudiced views towards affordable housing and distrust of the government, as well as fears that the character of Pacific Palisades would change. Some even floated the conspiracy that the fires were set on purpose to replace the wealthy community with one where homes were more affordable.
Regardless of whether the objections are based on conspiracy theories or fact, however, lawmakers have taken notice, and the controversial bill has now been put on pause.
"I appreciate the input of the folks who have weighed in about the bill, and along with legislative colleagues have decided that it would be best for us to pause the bill until next year to give us more time to see if we can get it right," State Senator Ben Allen said in a recent statement. "For me to feel comfortable proceeding, the bill will have to be deeply grounded in community input, empowerment, and decision-making, including the support of the impacted councilmembers."
What to read next
Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now
Accredited investors can now buy into this $22 trillion asset class once reserved for elites – and become the landlord of Walmart, Whole Foods or Kroger without lifting a finger. Here's how
Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead
Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you?
Stay in the know. Join 200,000+ readers and get the best of Moneywise sent straight to your inbox every week for free.
This article provides information only and should not be construed as advice. It is provided without warranty of any kind.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
– Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – SOUTH SAN FRANCISCO, Calif., July 28, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. "Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition." Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. "Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis," said Matt Sause, CEO of Roche Diagnostics. "Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families." Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Pharmaceuticals In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Diagnostics Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm - 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm - 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm - 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm - 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am - 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley About trontinemab Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. About Roche in Alzheimer's Disease With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact: Meghan Hindman (650) 467-6800Advocacy Contact: Jenee Williams (650) 303-2958Investor Contacts: Loren Kalm (650) 225-3217Bruno Eschli +41616875284 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Lakers rumors: Insider admits Luka Doncic not signing extension would be ‘shock'
The post Lakers rumors: Insider admits Luka Doncic not signing extension would be 'shock' appeared first on ClutchPoints. The Los Angeles Lakers have been making a few moves over the past few weeks, and it's not only to improve the team but to satisfy one of their star players. When Luka Doncic was traded to the Lakers last season, the vibe was that every move the Lakers made from then on would be to help Doncic, and that's what happened when Smart recently signed with them. Ultimately, the team aims to ensure Doncic remains a Laker for life, which means he must sign an extension with the team. As long as it may be taking for him to actually sign it, there is a lot of optimism surrounding him being with the Lakers now and in the future, according to ESPN's Ramona Shelburne. 'I'm going to say this—and I know I'll get aggregated—but I feel this strongly about it: I would be shocked if he didn't sign an extension,' Shelburne said via ESPN LA radio. Though Doncic didn't ask to get traded to the Lakers, it seems like he enjoys being in Los Angeles and is dedicated to bringing the team a championship. It also looks like the team is committed to listening to what he wants, which should give him a reason to want to stay. When will Luka Doncic sign his extension with the Lakers? After next season, Doncic can become a free agent if he declines his player option, and the Lakers do not want that. With how active he's been in helping the team during free agency, there is more confidence that he will end up signing the extension, according to NBA insider Marc Stein. 'External fretting about Doncic committing his long-term future to the Lakers, meanwhile, has dissipated considerably thanks to the contributions made by the 26-year-old throughout free agency in collaboration with vice president of basketball operations Rob Pelinka,' Stein wrote. 'Contact between Pelinka, Doncic and two pillars of Team Luka — chief brand officer and business manager Lara Beth Seager and longtime agent Bill Duffy — has been constant since a well-chronicled dinner at Craig's in West Hollywood shortly after L.A.'s first-round playoff elimination.' It would not be a surprise if Doncic signed the extension before the season started so they won't have to worry about it for the entire year. As of now, it looks like Doncic will be a Laker for a long time, and the team and fans have embraced him. Related: Lakers' Marcus Smart reveals Luka Doncic's recruiting pitch Related: Lakers' Marcus Smart signing draws 'winning' proclamation from Rob Pelinka
Yahoo
an hour ago
- Yahoo
Lakers rumors: Los Angeles ‘prioritizing' max salary cap space in 2027
The post Lakers rumors: Los Angeles 'prioritizing' max salary cap space in 2027 appeared first on ClutchPoints. The Los Angeles Lakers are once again making headlines—this time not for on-court moves, but for their long-term financial strategy. According to recent reports from Shams Charania, the Lakers are prioritizing 2027 salary cap flexibility, with plans to preserve space for a potential max-level free agent signing. This forward-looking approach follows LeBron James' player option decision and major roster changes, including the departure of Anthony Davis and the high-profile acquisition of Luka Doncic in a blockbuster trade earlier this year. According to Charania, who posted an update on X, formerly known as Twitter, James' mindset aligns with the Lakers' front office strategy. He exercised his player option with the belief that the team can add the right piece to help him chase a fifth championship—his top priority—while also understanding that the organization is preparing to build around Doncic as the franchise centerpiece. However, if the Lakers fall short of building a true contender, league insiders believe James could inform the front office he wants a trade—potentially leading to an in-season move based on how the situation unfolds. 'LeBron James understands the Lakers are prioritizing the future… That really centers around Luka Doncic… He wants to compete for a championship wherever that may be.' With James officially locked in for the 2025-26 season at $52.6 million, the player option adds short-term clarity while keeping long-term options open. This aligns with reports that the Lakers 2027 salary cap strategy centers around building a contender after LBJ's potential departure or final extension. The acquisition of Doncic was a franchise-altering move. The Slovenian superstar is expected to sign a long-term deal soon, with projections ranging from a three-year, $165 million option to a four-year, $229 million extension. It's clear the Doncic contract will play a central role in shaping the team's financial future, as the organization is fully committed to building a new era around him once he becomes eligible to sign an extension on August 2nd. By shedding long-term salary and avoiding bloated offseason deals, the Lakers are clearly positioning themselves to strike big in the 2027 free agency class, creating the financial flexibility needed to eventually pair Doncic with a high-level co-star once James exits or retires. With a combination of star power, short-term competitiveness, and forward-thinking planning, the Lakers are building around Doncic and positioning themselves for another franchise-defining splash in 2027—looking to maximize what remains of their time with James while preparing for the next chapter in Los Angeles. Related: Lakers' trade proposal for Robert Williams after Deandre Ayton buyout Related: Lakers rumors: What LA offered Dorian Finney-Smith before Rockets deal